Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
November 29, 2004
- Allowances Not Based on Clear Criteria Should Be Minimized: Mr Ohkita of JPMA
November 29, 2004
- R&D Productivity of Top Domestic Companies at Least 30% Less than Global Leaders: BCG Report
November 29, 2004
- 3rd Qtrs Business Results
November 29, 2004
- BULLETIN
November 29, 2004
- Asahi Kasei Pharma: Sales Down 2.1% at \52.7 Bil.
November 22, 2004
- MEDICAL DEVICE NEWS IN BRIEF
November 22, 2004
- Changing "Mevalotin Sankyo" into "CV Drug Sankyo": Mr Shoda
November 22, 2004
- Dainippon Preparing for Recovery in FY2005: Mr Miyatake
November 22, 2004
- Semiannual Business Results
November 22, 2004
- Sankyo: Tough Competition in Mevalotin Hurts Drug Division Sales
November 22, 2004
- Taiyo: Sales Up 11% to \12.4 Bil.
November 22, 2004
- TOPICS 2 articles
November 22, 2004
- Semiannual Business Results
November 22, 2004
- Towa: Consolidated Sales of \12.0 Bil. Posted
November 22, 2004
- BULLETIN
November 22, 2004
- Meet the Leaders (38)
November 22, 2004
- Towa Lowers Sales Forecast for Products Listed in July by 50%
November 22, 2004
- WORLD NEWS IN BRIEF
November 22, 2004
- CAGR of 7% in Sales, 15% in Operating Profits over 3 Years Targeted: Astellas
November 22, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…